<?xml version='1.0' encoding='utf-8'?>
<document id="27794414"><sentence text="Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer."><entity charOffset="25-34" id="DDI-PubMed.27794414.s1.e0" text="erlotinib" /><entity charOffset="39-48" id="DDI-PubMed.27794414.s1.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.27794414.s1.e0" e2="DDI-PubMed.27794414.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27794414.s1.e0" e2="DDI-PubMed.27794414.s1.e1" /></sentence><sentence text="Erlotinib, a substrate drug metabolized by the CYP3A4 enzyme, is an epidermal growth factor receptor tyrosine kinase inhibitor used to treat nonsmall cell lung cancer (NSCLC)"><entity charOffset="0-9" id="DDI-PubMed.27794414.s2.e0" text="Erlotinib" /><entity charOffset="101-109" id="DDI-PubMed.27794414.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.27794414.s2.e0" e2="DDI-PubMed.27794414.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27794414.s2.e0" e2="DDI-PubMed.27794414.s2.e1" /></sentence><sentence text=" Concomitant use of erlotinib and the antiepileptic drug phenytoin, an inducer of CYP3A4, may result in a drug-drug interaction accompanied by changes in the blood concentrations of both drugs"><entity charOffset="20-29" id="DDI-PubMed.27794414.s3.e0" text="erlotinib" /><entity charOffset="57-66" id="DDI-PubMed.27794414.s3.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.27794414.s3.e0" e2="DDI-PubMed.27794414.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27794414.s3.e0" e2="DDI-PubMed.27794414.s3.e1" /></sentence><sentence text=" We determined the blood concentration of each drug to confirm the interaction between phenytoin and erlotinib in a case of NSCLC with brain metastases"><entity charOffset="87-96" id="DDI-PubMed.27794414.s4.e0" text="phenytoin" /><entity charOffset="101-110" id="DDI-PubMed.27794414.s4.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.27794414.s4.e0" e2="DDI-PubMed.27794414.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27794414.s4.e0" e2="DDI-PubMed.27794414.s4.e1" /></sentence><sentence text=" The phenytoin blood concentration (8"><entity charOffset="5-14" id="DDI-PubMed.27794414.s5.e0" text="phenytoin" /></sentence><sentence text="2-10" /><sentence text="0μg/mL) gradually increased 3-fold (to 24" /><sentence text="2μg/mL) 7 months after the start of erlotinib (150mg/d) co-administration"><entity charOffset="36-45" id="DDI-PubMed.27794414.s8.e0" text="erlotinib" /></sentence><sentence text=" The erlotinib blood concentration which was maintained at 0"><entity charOffset="5-14" id="DDI-PubMed.27794414.s9.e0" text="erlotinib" /></sentence><sentence text="15-0" /><sentence text="37μg/mL under phenytoin co-administration, increased 12-fold (to 1"><entity charOffset="14-23" id="DDI-PubMed.27794414.s11.e0" text="phenytoin" /></sentence><sentence text="77μg/mL) after the stoppage of phenytoin co-administration"><entity charOffset="31-40" id="DDI-PubMed.27794414.s12.e0" text="phenytoin" /></sentence><sentence text=" The present case revealed that blood phenytoin increased and blood erlotinib decreased subsequent to the interaction of the 2 drugs in the CYP3A4 metabolic enzyme system"><entity charOffset="38-47" id="DDI-PubMed.27794414.s13.e0" text="phenytoin" /><entity charOffset="68-77" id="DDI-PubMed.27794414.s13.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.27794414.s13.e0" e2="DDI-PubMed.27794414.s13.e0" /><pair ddi="false" e1="DDI-PubMed.27794414.s13.e0" e2="DDI-PubMed.27794414.s13.e1" /></sentence><sentence text="" /></document>